Accelerate Vaccine Development
Explore how Dextramer® reagents can help you monitor antigen-specific immune cells
Cutting Edge Reagents for Detection of Antigen-Specific Immune Cells
Regardless of the vaccine type, vaccine development usually follows a rigid process.
Dextramer® technology can help you uncover antigen-specific immune cell responses and provide new insights into vaccine therapeutic efficacy and toxicity.
Explore Our Vaccine Development Solutions
Get the full picture of the cellular immune response
Expand the limits of your research
Ensure consistent, reproducible, and comparable results
Secure flexibility in your experiments
Immudex is Your Trusted Partner in All the Phases of Vaccine Development
Perform massive multiplexing of antigen specificities in epitope discovery or neoantigen screenings by NGS using our dCODE Dextramer® and dCODE Klickmer® technology.
Detect, monitor, and document the presence or responses of antigen‑specific immune cells in preclinical efficacy studies using MHC I or II Dextramer® and Klickmer® by flow cytometry.
Detect and monitor antigen‑specific T-cell
responses in clinical trials using our Clinical‑Grade MHC Dextramer® (GMP) reagents that meet numerous requirements in accordance with quality system requirements for medical devices defined by ISO 13485 and 21 CFR 820.
Want to Hear More About Our Vaccine Development Solutions?
Fill in the form and one of our dedicated specialists will get in touch with you shortly